期刊文献+

右旋糖酐阿司匹林偶联物的合成 被引量:5

Synthesis of Dextran-aspirin Conjugate
下载PDF
导出
摘要 以右旋糖酐和乙酰水杨酰氯为原料,合成了高分子偶联物右旋糖酐 阿司匹林,并用FTIR、1HNMR对其结构进行了表征。考察了缚酸剂、右旋糖酐重均相对分子质量、反应温度和物料比对酯化反应的影响。结果表明,三乙胺和吡啶均可作为该酯化反应的缚酸剂,而浓氢氧化钠水溶液则不适合;乙酰水杨酰基的接入率随右旋糖酐重均相对分子质量的增大而减小,但随乙酰水杨酰氯与右旋糖酐的质量比的增加而增大;当选用Mw=20 000的右旋糖酐、缚酸剂三乙胺,反应温度在 60℃左右、m(乙酰水杨酰氯) /m(右旋糖酐 ) =3. 06时,乙酰水杨酰基的接入率和其有效转化率分别为 9. 30%和 3 .07%。 In order to obtain a sustained release aspirin derivative having less side-effect on gastrointestinal tract,dextran-aspirin conjugate was prepared by coupling reaction between o-acetoxybenzoyl chloride and dextran.Its structure was characterized with FTIR and ~1HNMR.Influences of various factors,such as acid absorbent,molecular weight of dextran,reaction temperature and mass ratio of reactants,on this reaction were investigated.UV spectrum was applied to evaluate the drug-loading ratio of dextran-aspirin conjugate produced under different reaction conditions.The results show that both triethylamine and pyridine are effective acid absorbents in this reaction,while sodium hydroxide solution could not be used as acid absorbent.The drug-loading ratio of dextran-aspirin conjugate decreases with increase in average molecular weight of dextran,while increases with increase in mass ratio of o-acetoxybenzoyl chloride to dextran.Thus,reaction of o-acetoxybenzoyl chloride and dextran having average molecular weight of 20,000 in mass ratio of 3.06 was carried out at 60 ℃,using dimethyl sulphoxide as solvent and triethylamine as acid absorbent.Under these optimum reaction conditions,the drug-loading ratio about 9.30% and the converting efficency about 3.07% were attained.
出处 《精细化工》 EI CAS CSCD 北大核心 2005年第3期205-208,共4页 Fine Chemicals
关键词 右旋糖酐-阿司匹林偶联物 右旋糖酐 阿司匹林 dextran-aspirin conjugate dextran aspirin
  • 相关文献

参考文献14

  • 1阮吉敏,潘泳康,陈其,周达飞.GMA固相接枝PP的研究[J].高分子材料科学与工程,1999,15(1):80-83. 被引量:20
  • 2John L W,Louis J I,Stefano F.Potential cardioprotective action of no-releasing aspirin[J].Nature Review,Drug Discovery,2002,1:372-375. 被引量:1
  • 3Patrono C.Aspirin as an antiplatelet drug[J].New England Journal of Medicine,1994,330 (18):1287-1294. 被引量:1
  • 4Robert S,Sandler M D,Susan H,et al.A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer[J].New England Journal of Medicine,2003,348 (10):883-890. 被引量:1
  • 5Berman K S,Hassan Y,Cole B F,et al.Aspirin and the prevention of colorectal cancer[J].New England Journal of Medicine,2003,348 (24):2466-2467. 被引量:1
  • 6Dyer O.Aspirin could be used to prevent cancer[J].British Medical Journal,2003,326 (5):561-565. 被引量:1
  • 7耿洪业 王少华.实用治疗药物学(第2版)[M].北京:人民卫生出版社,2001.427-437. 被引量:3
  • 8Wallace J L.Gastrointestinal sparing anti-inflammatory drugs:the development of nitric oxide-relasing NSAIDs[J].Drug Development Research,1997,42(2):144-149. 被引量:1
  • 9Bandarage U K.Nitrosothiol esters of diclofenac:synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs[J].Journal of Medical Chemistry,2000,43(36):4005-4016. 被引量:1
  • 10Won C Y,Chu C C.Dextran-estrone conjugate:synthesis and in vitro release study[J].Carbohydrate Polymers,1998,36(4):327-334. 被引量:1

二级参考文献11

共引文献27

同被引文献69

  • 1张骁.短信息[J].中国制药信息,2006,22(1):15-17. 被引量:2
  • 2温晓娜,毛静怡.非甾体抗炎药的不良反应[J].中国药师,2006,9(10):959-960. 被引量:24
  • 3Taylor C, Cheetham N W H, Walker G J. Carbohydr Res, 1985, 1: 137. 被引量:1
  • 4Jeanes A, Haynes W C, Wilham C A, et al. Chem Soc, 1954, 76: 5041. 被引量:1
  • 5Vandamme E J, Bruggeman G, DeBaets S, et al. Agro-Food-Ind Hi-Tech, 1996(7): 21. 被引量:1
  • 6EISeoud O, Heinze T, Springer. Polysaccharide I [J]. Advances in Polymer Science, 2005, 186: 103. 被引量:1
  • 7Heinze T, Dumitriu S, Marcel Dekker. Chemical functionalization of cellulose[J]. The Prokaryotes, 2004(2): 551. 被引量:1
  • 8Larm O, Lindberg B, Svensson S. Carbohydr Res, 1971, 20: 39;. 被引量:1
  • 9Cheetham N W H, Fiala-Beer E. Carbohydr Polym, 1991, 14: 149. 被引量:1
  • 10Heinze T, Liebert T. Macromol Symp, 2004, 208: 167. 被引量:1

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部